Clinical trial

A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)

Active, not recruiting · Phase 1 · 1 countries · Registry ID NCT07388667

Active, not recruitingPhase 1Interventional

What this study is about

Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) of the study medicine that can be used in future studies. The goals of this study are to learn about: * The safety of MK-4082 and if people tolerate it * What happens to different MK-4082 dose levels in a person's body over time

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 60 Years
SexAll
Healthy volunteersAccepted
ConditionHealthy

Full registry criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) between 25 and 40 kg/m\^2, inclusive. Participants must weigh at least 60 kg Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * has a history of previous surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or any other gastrointestinal (GI) surgery that may induce malabsorption, history of bowel resection \>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss (including LAP-BAND®), as well as clinically significant GI disorders (eg, peptic ulcers, severe gastroesophageal reflux disease) * has an individual or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 2

Treatments and study arms

MK-4082

Drug

Oral Tablet

Placebo

Drug

Oral Tablet

Primary outcomes

Number of Participants Who Experience an Adverse Event (AE)Up to approximately 98 Days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

Number of Participants Who Discontinue Study Treatment Due to an AEUp to approximately 84 Days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Study locations

5 locations were listed when this page was built. The first 40 are shown.

Anaheim Clinical Trials ( Site 0005)🇺🇸 Anaheim, California, United States
ProSciento Inc. ( Site 0002)🇺🇸 Chula Vista, California, United States
Hassman Research Institute Marlton Site ( Site 0006)🇺🇸 Marlton, New Jersey, United States
QPS-MRA, LLC ( Site 0003)🇺🇸 South Miami, Florida, United States
Bio-Kinetic Clinical Applications, LLD dba QPS-MO ( Site 0004)🇺🇸 Springfield, Missouri, United States